Browse by Industry
Filter News
Found 808,462 articles
-
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound.
-
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.
-
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.
-
After withdrawing ALS drug Relyvrio from the U.S. and Canadian markets and laying off 70% of its workforce, the Cambridge, Mass.–based biopharma got a much-needed win in Wolfram syndrome.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
Amylyx looks to the future after Relyvrio withdrawal, ADCs continue to attract investment and the drug shortage persists in the U.S.
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
The Menlo Park, Calif.-based venture capital firm has raised more than $1 billion since last year, with this latest injection of capital going to its biopharma investment funds.
-
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
-
Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus erythematosus.
-
GSK’s antibiotic eliminated the bacterial cause of gonorrhea in 92.6% of patients in a Phase III study, while its Shingrix vaccine’s efficacy in shingles remained above 70% over 11 years of follow up.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance
4/17/2024
InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT ™ platform, with the GastroPlus ® and ADMET Predictor ® modelling software offered by Simulations Plus.
-
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
4/17/2024
ABVC BioPharma, Inc. announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX.
-
SalioGen Therapeutics Announces Selection of Development Candidate for ABCA4-mediated Stargardt Disease
4/17/2024
SalioGen Therapeutics today announced the nomination of a development candidate, SGT-1001, for the treatment of Stargardt disease, a rare and progressive inherited retinal disease.
-
X-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)
4/17/2024
X-Therma Inc , announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive ® .
-
Biopharmaceutical Fermentation Market Size Expected to Reach USD 16.03 Billion to 2031
4/17/2024
Global Biopharmaceutical Fermentation Market is valued at US$ 10.17 Bn in 2023, and it is expected to reach US$ 16.03 Bn by 2031, with a CAGR of 6.11% during the forecast period of 2024-2031.
-
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
4/17/2024
Hyperfine, Inc. today announced that the first patients have been enrolled in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study.